Nephrol Dial Transplant (2001) 16: 82-84
© 2001 European Renal Association-European Dialysis and Transplant Association
Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure
Nephrology Unit, Fundació Puigvert and 1 Hospital Clinic, Nephrology Service, Barcelona, Spain
Background. The aim of the present study was to investigate the effect of losartan on the progression of renal function in non-diabetic patients with chronic renal failure in an open, prospective, follow-up study of 1 year.
Methods. Twenty-nine hypertensive patients (14 females and 15 males; mean age 63 years.) with non-diabetic chronic renal failure of several causes received losartan 50 mg/day (plus other antihypertensive agents if needed) and were followed-up prospectively during 13±1 months. Eighteen patients received angiotensin-converting enzyme inhibitors plus other antihypertensive drugs at baseline. Patients had been followed-up for 44±4 months prior to the treatment with losartan. The rate of progression of renal insufficiency was evaluated as the slope of the reciprocal of serum creatinine vs time in months.
Results. Blood pressure, creatinine clearance and urinary protein excretion at baseline and after 1 year of treatment with losartan were: 149±3/90±1 vs 142±2/84±1 mmHg (P<0.01/P<0.05), 29±3 vs 29±3 ml/min (P=NS), and 1.7±0.4 vs 1.2±0.2 g/24 h (P=0.11, NS). Serum creatinine at baseline, and after 6 months and 1 year of treatment with losartan was: 3.18±0.24, 3.24±0.27 (P=NS vs baseline) and 3.49±0.32 mg ml (P<0.05 vs baseline). The rate of progression of renal disease before and after 1 year of treatment with losartan was -0.0039±0.0058 vs -0.0012±0.0073 mg/month (P<0.01). Changes in proteinuria after 1 year of treatment with losartan correlated with the change in renal disease progression (r=-0.519, P<0.01).
Conclusions. The rate of progression of renal function in patients with non-diabetic chronic renal failure is slowed down after 1 year of treatment with losartan. The results of this preliminary study suggest that AT1 receptor blockade treatment offers renoprotection in this subset of patients, although these results need to be confirmed in appropriate controlled trials.
Keywords: chronic renal failure, hypertension; losartan; renal disease progression
Correspondence and offprint requests to: Dr José Mora-Maciá, Servicio de Nefrología, Fundació Puigvert, C/Cartagena 340–350, 08025-Barcelona, Spain.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Akbari, G. Knoll, D. Ferguson, B. McCormick, A. Davis, and M. Biyani ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PERITONEAL DIALYSIS: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Perit. Dial. Int., September 1, 2009; 29(5): 554 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Xue, J. Z. Ma, T. A. Louis, and A. J. Collins Forecast of the Number of Patients with End-Stage Renal Disease in the United States to the Year 2010 J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2753 - 2758. [Abstract] [Full Text] [PDF]
|
|